Trading Center
ARNA Forum Topics
- All Comments on ARNA
- General Discussion on ARNA
- Arena Pharmaceuticals, Inc. Q1 2008 Earnings Call Transcript [view article]
- Arena Pharmaceuticals Q4 2007 Earnings Call Transcript [view article]
- Safety Data on Arena's Weight Loss Drug Could Pave Way for Good Partnership [view article]
- 2007 Biotech Performance Review [view article]
- Expecting a Strong Move in Arena Pharma [view article]
- Companies With The Most Analyst Attention & Affection [view article]
- Jim Cramer's Mad Money In-Depth Stock Picks, Oct. 3 [view article]
Recent ARNA Articles
- Safety Data on Arena's Weight Loss Drug Could Pave Way for Good Partnership
- 2007 Biotech Performance Review
- Expecting a Strong Move in Arena Pharma
- Companies With The Most Analyst Attention & Affection
- Biotech Day In Review: Sanofi-Aventis Lands Cancer Vaccine For $680 Million
- Biotech Day in Review: Lilly Buys Insomnia-Focused Hypnion
- Biotech Day in Review: Wyeth and AstraZeneca Sign More Deals
- Biotech Rises To New Record High
- Full List of Articles »
loading ...
Companies With The Most Analyst Attention & Affection [view article]
Have you guys run anything on the other side of the list -- the companies with low to no coverage? ReplyMetzinger
Jim Cramer's Mad Money In-Depth Stock Picks, Oct. 3 [view article]
Ben:Thank you very much for the feedback. I have made the correction and apologize for the confusion.
Miriam Metzinger
Seeking Alpha Reply
Jim Cramer's Mad Money In-Depth Stock Picks, Oct. 3 [view article]
Cramer did NOT say "(A)lthough MOT and CSCO could overwhelm DivX...." He was speaking about Arris (ARRS), not DivX. He had just explained that Arris is a competitor of MOT and CSCO. Obviously, DivX is not. This should be corrected with "Arris" substituted for "DivX" in Miriam Metzinger's summary. Reply